HomeCompareVMTHF vs NOBL

VMTHF vs NOBL: Dividend Comparison 2026

VMTHF yields 474.05% · NOBL yields 4.00%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VMTHF wins by $40760.08M in total portfolio value
10 years
VMTHF
VMTHF
● Live price
474.05%
Share price
$0.42
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40760.11M
Annual income
$28,806,329,273.60
Full VMTHF calculator →
NOBL
NOBL
● Live price
4.00%
Share price
$50.00
Annual div
$2.00
5Y div CAGR
5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.0K
Annual income
$899.19
Full NOBL calculator →

Portfolio growth — VMTHF vs NOBL

📍 VMTHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVMTHFNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VMTHF + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VMTHF pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VMTHF
Annual income on $10K today (after 15% tax)
$40,293.91/yr
After 10yr DRIP, annual income (after tax)
$24,485,379,882.56/yr
NOBL
Annual income on $10K today (after 15% tax)
$340.00/yr
After 10yr DRIP, annual income (after tax)
$764.31/yr
At 15% tax rate, VMTHF beats the other by $24,485,379,118.25/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VMTHF + NOBL for your $10,000?

VMTHF: 50%NOBL: 50%
100% NOBL50/50100% VMTHF
Portfolio after 10yr
$20380.07M
Annual income
$14,403,165,086.40/yr
Blended yield
70.67%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VMTHF buys
0
NOBL buys
0
No recent congressional trades found for VMTHF or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVMTHFNOBL
Forward yield474.05%4.00%
Annual dividend / share$2.00$2.00
Payout ratio50%50%
1-year div growth0%5%
5-year div CAGR0%5%
Portfolio after 10y$40760.11M$28.0K
Annual income after 10y$28,806,329,273.60$899.19
Total dividends collected$39707.63M$6.4K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: VMTHF vs NOBL ($10,000, DRIP)

YearVMTHF PortfolioVMTHF Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$58,105$47,404.60$11,120$420.00+$47.0KVMTHF
2$319,595$257,422.91$12,357$458.31+$307.2KVMTHF
3$1,665,249$1,323,282.78$13,721$499.76+$1.65MVMTHF
4$8,225,711$6,443,893.93$15,227$544.58+$8.21MVMTHF
5$38,549,580$29,748,069.43$16,885$593.02+$38.53MVMTHF
6$171,541,094$130,293,043.94$18,713$645.34+$171.52MVMTHF
7$725,407,583$541,858,612.30$20,724$701.81+$725.39MVMTHF
8$2,917,676,445$2,141,490,330.46$22,938$762.73+$2917.65MVMTHF
9$11,171,756,198$8,049,842,402.84$25,372$828.41+$11171.73MVMTHF
10$40,760,108,406$28,806,329,273.60$28,047$899.19+$40760.08MVMTHF

VMTHF vs NOBL: Complete Analysis 2026

VMTHFStock

Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.

Full VMTHF Calculator →

NOBLETF

NOBL is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in NOBL shares.

Full NOBL Calculator →
📬

Get this VMTHF vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VMTHF vs SCHDVMTHF vs JEPIVMTHF vs OVMTHF vs KOVMTHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.